Protective effect of CCR5-Δ32 against hiv infection by the heterosexual mode of transmission in a polish population

AIDS Research and Human Retroviruses

Volumn 29, Issue 1, 2013, Pages 54-60

  Zwolińska, Katarzyna ^a   Knysz, Brygida ^b   Rybka, Katarzyna ^a   Pazgan Simon, Monika ^b   Gsiorowski, Jacek ^b   Sobczyński, MacIej ^c   Gładysz, Andrzej ^b   Piasecki, Egbert ^a,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF WROC AW   (Poland)

^d JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HETEROSEXUALITY; HETEROZYGOTE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; POLAND; PRIORITY JOURNAL; PROTEIN EXPRESSION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALLELES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROSEXUALITY; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLAND; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, CCR2; RECEPTORS, CCR5; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84871890223     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0362     Document Type: Article

References (41)

1. Baribaud F and Doms RW: The impact of chemokine receptor conformational heterogeneity on HIV infection. Cell Mol Biol 2001;47:653-660. 2. Hogan CM and Hammer SM: Host determinants in HIV infection and disease.
2. Genetic factors and implication for antiretroviral therapeutics. Ann Intern Med 2001;134:978-996.
3. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, and Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR- 5 chemokine receptor gene. Nature 1996;22:722-725.
4. Moore JP, Kitchen SG, Pugach P, and Zack J: The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004;20:111-126.
5. Martinson JJ, Chapman NH, Rees DC, Liu YT, and Clegg JB: Global distribution of the CCR5 gene 32-base pair deletion. Nat Genet 1997;16:100-103.
6. Libert F, Cochaux P, Beckman G, Samson M, Aksenova M, Cao A, Czeizel A, Claustres M, de la Ru'a C, Ferrari M, Ferrec C, Glover G, Grinde B, Guran S, Kucinskas V, Lavinha J, Mercier B, Ogur G, Peltonen L, Rosatelli C, Schwartz M, Spitsyn V, Timar L, Beckman L, Parmentier M, and Vassart G: The DCCR5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in northeastern Europe. Hum Mol Genet 1998;7:399-406.
7. O'Brien JP and Moore SJ: The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000;177:99-111.
8. Arenzana-Seisdedos F and Parmentier M: Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 2006;18:387-403.
9. Lama J and Planelles V: Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology 2007;4:52.
10. Oh DY, Jessen H, Kucherer C, Neumann K, Oh N, Poggensee G, Bartmeyer B, Jessen A, Pruss A, Schumann RR, and Hamouda O: CCR5D32 genotypes in German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5D32 homozygous individual. PLoS One 2008; 3:e2747.
11. Kaslow RA, Dorak T, and Tang J: Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis 2005;191(Suppl 1):68-77.
12. Klein RS: A moving target: The multiple roles of CCR5 in infectious diseases. J Infect Dis 2008;197:183-186.
13. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, McDermott DH, and Murphy PM: Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: A meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-265.
14. Kindberg E, Mickiene A, Ax C, A° kerlind B, Vene S, Lindquist L, Lundkvist A°, and Svensson L: A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008;197:266-269.
15. Keynan Y, Juno J, Meyers A, Ball TB, Kumar A, Rubinstein E, and Fowke KR: Chemokine receptor 5 D32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis 2010;16:1621-1622.
16. Trecarichi EM, Tumbarello M, de Gaetano Donati K, Tamburrini E, Cauda R, Brahe C, and Tiziano FD: Partial protective effect of CCR5-D32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Res Ther 2006;3:22.
17. Sei S, Boler AM, Nguyen GT, Stewart SK, Yang QE, Edgerly M, Wood LV, Brouwers P, and Venzon DJ: Protective effect of CCR5D32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection. AIDS 2001;15:1343-1352.
18. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, Jamieson BD, Meyer L, Michael NL, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Theodorou ID, Vlahov D, and Rosenberg PS: Effects of CCR5-D32 and CCR2-64I alleles on HIV-1 disease progression: The protection varies with duration of infection. AIDS 2003;17:377-387.
19. Narter KF, Agachan B, Sozen S, Cincin ZB, and Isbir T: CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res 2010;9:685-692.
20. Yeh CB, Tsai HT, Chen YC, Kuo WH, Chen TY, Hsieh YH, Chou MC, and Yang SF: Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol 2010;102:264-270.
21. Chen MK, Yeh KT, Chiou HL, Lin CW, Chung TT, and Yang SF: CCR2-64I gene polymorphism increase susceptibility to oral cancer. Oral Oncol 2011;47:577-582.
22. Knysz B, Rybka K, Gasiorowski J, Piasecki E, Zalewska M, and G1adysz A: Acid labile interferon a concentration: Prognostic value during immune reconstitution following effective antiretroviral therapy in HIV-1 positive patients. HIV AIDS Rev 2006;5:7-12.
23. Piasecki E, Knysz B, Zwoliń ska K, Gasiorowski J, Lorenc M, Zalewska M, G1adysz A, Siemieniec I, and Pazgan-Simon M: Inhibition of vesicular stomatitis virus replication in thecourse of HIV infection in patients with different stages of immunodeficiency. Viral Immunol 2010;23:567-576.
24. Zwoliń ska K: Host genetic factors associated with susceptibility to HIV infection and progression of infection. Postepy Hig Med Dosw 2009;63:73-91.
25. National AIDS Centre: Epidemiology: Poland. Available at www.aids.gov.pl/indexen.php?page = epidemiologia&act = pl (accessed September 2012).
26. Smith KM, Crandall KA, Kneissl ML, and Navia BA: PCR detection of host and HIV-1 sequences from archival brain tissue. J Neurovirol 2000;6:164-171.
27. Hersberger M, Marti-Jaun J, Hanseler E, and Speck RF: Rapid detection of the CCR2-V64I, CCR5-A59029G and SDF1- G801A polymorphisms by tetra-primer PCR. Clin Biochem 2002;35:399-403.
28. Bogner JR, Lutz B, Klein HG, Pollerer C, Troendle U, and Goebel FD: Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med 2004;5:264-272.
29. Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, McDermott DH, Murphy PM, and Alkhatib G: Role for CCR5D32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol 2004;78:2277-2287.
30. Reiche EM, Ehara Watanabe MA, Bonametti AM, Morimoto HK, Akira Morimoto A, Wiechmann SL, Matsuo T, Carvalho De Oliveira J, and Vissoci Reiche F: Frequency of CCR5-D32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population. Int J Mol Med 2008;22:669-675.
31. Jagodziń ski P, Lecyby1 R, Ignacak M, Juszczyk J, and Trzeciak W: Distribution of D32 allele of the CCR5 gene in the population of Poland. J Hum Genet 2000;45:271-274.
32. Zawicki P and Witas HW: HIV-1 protecting CCR5-D32 allele in medieval Poland. Infect Genet Evol 2008;8:146-151.
33. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, Corvasce S, Corbellino M, Clementi M, Clerici M, Moroni M, and Galli M: Homozygous D32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997;11:67-71.
34. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofman J, Kucherer C, Blau O, Blau IW, and HofmannWK, Thiel E: Long-term control of HIV by CCR5D/D stem cell transplantation. N Engl J Med 2009;360:692-698.
35. Hutter G, Schneider T, and Thiel E: Transplantation of selected or transgenic blood stem cells - a future treatment for HIV/AIDS? J Int AIDS Soc 2009;12:10.
36. Mangano A, Kopka J, Batalla M, Bologna R, and Sen L: Protective effect of CCR2-64I and not of CCR5-D32 and SDF1-3¢A in pediatric HIV-1 infection. J Acquir Immune Defic Syndr 2000;23:52-57.
37. Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, and Seage GR III; HIV Network for Prevention Trials Vaccine Preparedness Protocol Team: Homozygous and heterozygous CCR5-D32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001;27:472-481.
38. Philpott S, Weiser B, Tarwater P, Vermund SH, Kleeberger CA, Gange SJ, Anastos K, Cohen M, Greenblatt RM, Kovacs A, Minkoff H, Young MA, Miotti P, Dupuis M, Chen CH, and Burger H: CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis 2003;187:569-575.
39. Mahajan SD, Agosto-Mojica A, Aalinkeel R, Reynolds JL, Nair BB, Sykes DE, Martinez J, Adams J, Singh N, Bernstein Z, Hsiao CB, and Schwartz SA: Role of chemokine and cytokine polymorphisms in the progression of HIV-1 disease. Biochem Biophys Res Commun 2010; 396:348-352.
40. Poropatich K and Sullivan DJ Jr: Human immunodeficiency virus type 1 long-term non-progressors: The viral, genetic and immunological basis for disease non-progression. J Gen Virol 2011;92:247-268.
41. Malhotra R, Hu L, Song W, Brill I, Mulenga J, Allen S, Hunter E, Shrestha S, Tang J, and Kaslow RA: Association of chemokine receptor gene (CCR2-CCR5) haplotypes with acquisition and control of HIV-1 infection in Zambians. Retrovirology 2011;8:22.